Alzheimer's disease (AD) is considered to be the most common and the fastest growing neurological disease in the world. Biomarker tools for early diagnosis and disease progression in AD remain key issues for clinical applications (patient's control and monitoring), sanitary systems (growth of prevalence of AD in the near future), and pharmaceutical companies (drug developments). Electroencephalogram (EEG) yields, in principle, a powerful and relatively cheap way for screening of dementia and AD in their early stages although not reaching the specificity prescribed for clinical use. Portable EEG systems based on wireless sensors can be used for unobtrusive long term monitoring provided they can solve technological problems (e.g., size and op...
As medicinal and technological advances lengthen the average human life span, diseases affecting the...
Alzheimer’s Disease (AD) stands out as one of the main causes of dementia worldwide and it represen...
Recent experimental evidence has suggested a neuromodulatory deficit in Alzheimer's disease (AD). In...
Alzheimer's disease (AD) is considered to be the most common and the fastest growing neurological di...
Alzheimer’s disease (AD) is a progressive disorder that affects cognitive brain functions and starts...
Objective. EEG has great potential as a cost-effective screening tool for Alzheimer's disease (AD). ...
Early detection is crucial to control the progression of Alzheimer's disease and to postpone intelle...
Mild cognitive impairment (MCI) can be an indicator representing the early stage of Alzheimier’s dis...
Alzheimer's disease (AD) is a neurodegenerative disorder that causes a loss of connections between n...
Alzheimer's disease (AD) and dementia are the most common neurodegenerative disorder. Since the numb...
This study addresses the problem of Alzheimer's disease (AD) diagnosis with Electroencephalography (...
Background and objective: Electroencephalogram (EEG) is one of the most demanded screening tools tha...
Biomarkers to detect Alzheimer’s disease (AD) would enable patients to gain access to appropriate se...
This study will concentrate on recent research on EEG signals for Alzheimer’s diagnosis, identifying...
Alzheimer’s disease (AD) is a non-curable neuro-degenerative disorder that has no cure to date. Howe...
As medicinal and technological advances lengthen the average human life span, diseases affecting the...
Alzheimer’s Disease (AD) stands out as one of the main causes of dementia worldwide and it represen...
Recent experimental evidence has suggested a neuromodulatory deficit in Alzheimer's disease (AD). In...
Alzheimer's disease (AD) is considered to be the most common and the fastest growing neurological di...
Alzheimer’s disease (AD) is a progressive disorder that affects cognitive brain functions and starts...
Objective. EEG has great potential as a cost-effective screening tool for Alzheimer's disease (AD). ...
Early detection is crucial to control the progression of Alzheimer's disease and to postpone intelle...
Mild cognitive impairment (MCI) can be an indicator representing the early stage of Alzheimier’s dis...
Alzheimer's disease (AD) is a neurodegenerative disorder that causes a loss of connections between n...
Alzheimer's disease (AD) and dementia are the most common neurodegenerative disorder. Since the numb...
This study addresses the problem of Alzheimer's disease (AD) diagnosis with Electroencephalography (...
Background and objective: Electroencephalogram (EEG) is one of the most demanded screening tools tha...
Biomarkers to detect Alzheimer’s disease (AD) would enable patients to gain access to appropriate se...
This study will concentrate on recent research on EEG signals for Alzheimer’s diagnosis, identifying...
Alzheimer’s disease (AD) is a non-curable neuro-degenerative disorder that has no cure to date. Howe...
As medicinal and technological advances lengthen the average human life span, diseases affecting the...
Alzheimer’s Disease (AD) stands out as one of the main causes of dementia worldwide and it represen...
Recent experimental evidence has suggested a neuromodulatory deficit in Alzheimer's disease (AD). In...